Liver stiffness assessed by fibrosis-4 index; noninvasive marker using serum biomarkers is associated with right ventricular function and cardiovascular prognosis in HFpEF

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Mitsutaka Nakashima

Okayama University Hospital, Okayama (Japan)

9 More presentations in this session

Presentation thumbnail

Trans-catheter or surgical mitral valve procedure versus conservative treatment in heart failure patients with preserved ejection fraction

Doctor X. Sun (Rochester, US)

Abstract Slides

Presentation thumbnail

Inhaled iloprost improves echocardiographic myocardial performance during exercise in heart failure with preserved ejection fraction

Doctor C. Huang (Taipei, TW)

Presentation thumbnail

Impaired right ventricular force-frequency relationship in patients with heart failure is associated with diastolic dysfunction and worse functional capacity

Doctor A. Giammarresi (Bergamo, IT)

Abstract Slides

Presentation thumbnail

Clinical features associated with the development of diastolic dysfunction

Miss S. Bots (Utrecht, NL)

Abstract Slides

Presentation thumbnail

Analysis of myocardial work: a potential new tool for a better assessment of left ventricular function

Associate Professor R. Rimbas (Bucharest, RO)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 3 - Heart failure treatment, HFpEF, HFrEF

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

The role of a multimarker panel in the diagnosis and prognosis of patients with acute heart failure

Congress Session

From genetic signatures to clinical implications

Congress Presentation

Novel biomarkers reveal distinct biological phenotypes in heart failure with preserved vs reduced ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources